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Summary
 
Challenge of the airways of sensitized guinea pigs with aerosolized ovalbumin resulted in an
early phase of microvascular protein leakage and a delayed phase of eosinophil accumulation in
the airway lumen, as measured using bronchoalveolar lavage (BAL). Immunoreactive eotaxin
levels rose in airway tissue and BAL fluid to a peak at 6 h falling to low levels by 12 h. Eosino-
phil numbers in the tissue correlated with eotaxin levels until 6 h but eosinophils persisted until
the last measurement time point at 24 h. In contrast, few eosinophils appeared in BAL over the
first 12 h, major trafficking through the airway epithelium occurring at 12–24 h when eotaxin
levels were low. Constitutive eotaxin was present in BAL fluid. Both constitutive and allergen-
induced eosinophil chemoattractant activity in BAL fluid was neutralized by an antibody to eo-
taxin. Allergen-induced eotaxin appeared to be mainly in airway epithelium and macrophages,
as detected by immunostaining. Allergen challenge of the lung resulted in a rapid release of
bone marrow eosinophils into the blood. An antibody to IL-5 suppressed bone marrow eosin-
ophil release and lung eosinophilia, without affecting lung eotaxin levels. Thus, IL-5 and eo-
taxin appear to cooperate in mediating a rapid transfer of eosinophils from the bone marrow to
the lung in response to allergen challenge.
 
A
 
llergen provocation of allergic asthmatic patients re-
sults in an early phase of bronchoconstriction associ-
ated with cross-linking of IgE bound to Fc
 
e
 
RI receptors
on mast cells inducing degranulation, and a late phase
bronchoconstriction associated with the appearance of eo-
sinophils in the airways (1, 2). There is increasing evidence
linking the presence of eosinophils with airway damage and
dysfunction, but this remains controversial. The numbers
of eosinophils detected in bronchoalveolar lavage (BAL)
 
1
 
and airway mucosa correlate with the degree of lung dys-
function in asthmatics (3, 4). Moreover, eosinophils con-
tain chemicals as part of the host defense system against hel-
minths which, if misdirected, can damage airway mucosa
and lung tissue (5, 6). Some of these products, major basic
protein, eosinophil peroxidase (EPO), and eosinophil cat-
ionic protein, have been detected in BAL fluid from asth-
matics, a consequence of eosinophil degranulation in the
lung (6–8). Blood microvessels in the lung have an impor-
tant role, both as the route for entry of inflammatory cells
including T lymphocytes (particularly of the Th
 
2
 
 subset)
and eosinophils, and in terms of the extravascular supply of
plasma proteins through opening of interendothelial cell
junctions. The latter is manifest as increasing plasma albu-
min concentrations detectable in BAL fluid after allergen
challenge (9–11).
Knowledge concerning the mechanisms underlying al-
lergic inflammation in the asthmatic lung has grown through
observations made in patients and patient-derived samples,
together with observations made in animal systems which
model certain important features of the human condition.
Notable among the latter are studies in ovalbumin-sensitized
guinea pigs challenged with aerosolized allergen (12–15). On
allergen challenge, guinea pigs demonstrate immediate bron-
choconstriction associated with mast cell degranulation
resulting in histamine release and peptidoleukotriene secre-
tion, and a late response associated with eosinophil accu-
mulation in the airways.
 
1
 
Abbreviations used in this paper:
 
 BAL, bronchoalveolar lavage; EPO, eosin-
ophil peroxidase; i.d., intradermally.
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Recently we identified a small protein in BAL fluid from
ovalbumin-challenged, sensitized guinea pigs which is a
powerful and selective eosinophil chemoattractant. This pro-
tein was purified, sequenced, and found to be a 73–amino
acid CC chemokine which we called eotaxin (16). Murine
(17, 18) and human (19, 20) homologues have now been
identified, and have been found to act through an eotaxin
receptor, CCR3, present in high numbers on eosinophils
(21, 22). Allergen challenge of sensitized animals has been
shown to be associated with increased mRNA for eotaxin
in the lungs of both guinea pigs (23, 24) and mice (18).
We have now developed an immunoassay for guinea pig
eotaxin and this paper describes its use to analyze the rela-
tionship between the appearance of eotaxin protein and
eosinophil accumulation in the guinea pig allergic airways
model. Further, we have demonstrated recently a poten-
tially important interaction between eotaxin and IL-5 using
exogenous agents in vivo (25). This paper delineates the re-
lationship between endogenous eotaxin and IL-5 in the
context of the allergic reaction in the lung.
 
Materials and Methods
 
Animals.
 
Male Dunkin Hartley guinea pigs (Charles River
Laboratories, Margate, Kent, UK) were used for all the in vivo
procedures described. Female exbreeder guinea pigs from the
same source were used as eosinophil donors.
 
Materials.
 
Ovalbumin (grade V), Pyrilamine, BSA, hexade-
cyltrimethylammonium bromide, 
 
o
 
-phenylenediamine, hydrogen
peroxide, dexamethasone 21-phosphate, 
 
n
 
-octanoic acid, Freund’s
adjuvants, and control rat IgG were purchased from Sigma
Chemical Co. (Poole, Dorset, UK). Aluminum hydroxide, low
viscosity fluid gel was from Wilfred Smith Ltd. (Middlesex, UK).
HBSS and Hepes were from Life Technologies (Paisley, UK). Io-
dogen reagent was from Pierce and Warriner (Chester, UK).
Na
 
125
 
I and 
 
111
 
InCl
 
3
 
 were from Amersham International (Bucking-
hamshire, UK). Goat anti–rabbit IgG second antibody for RIA was
from Nordic Immunological Laboratories (Tilburg, The Nether-
lands). mAbs and substrate for immunohistochemistry were from
Dako (High Wycombe, Buckinghamshire, UK). C18 reversed phase
SepPak cartridges were from Millipore (Watford, UK). Percoll
and protein A–Sepharose were from Pharmacia Biotech (St Al-
bans, Hertfordshire, UK).
Eotaxin for use in skin bioassays was purified from the BAL
fluid of allergen-challenged guinea pigs as described previously (16).
TRFK5 mAb was a gift from Dr. Paul Hiss (Glaxo-Wellcome,
Stevenage, Hertfordshire, UK).
 
Sensitization and In Vivo Allergen Challenge of Guinea Pigs.
 
Guinea pigs (200–250 g) were sensitized with an i.p. injection of
ovalbumin (10 
 
m
 
g) mixed with aluminum hydroxide (2 mg) in 1 ml
of saline on days 1 and 15. On day 28, animals were pretreated
with pyrilamine (10 mg/kg, i.p.), to prevent acute fatality, and
exposed to aerosolized ovalbumin (1%) or saline for 20 min. At
different times after allergen challenge, animals were treated with
atropine (0.06 mg/kg, i.p.), to prevent bronchoconstriction, and
killed with a barbiturate overdose. BAL was performed with 15 ml
of saline (containing EDTA and Hepes, each at 10 mM) and the
fluid centrifuged at 4
 
8
 
C for 10 min at 400 
 
g.
 
 BAL cells were re-
suspended in HBSS (containing EDTA, Hepes, and 0.25% BSA)
and total cell counts determined using Kimura stain. The 400 
 
g
 
supernatant was centrifuged again (3,470 
 
g
 
, 20 min at 4
 
8
 
C) and
the resulting supernatant stored at 
 
2
 
20
 
8
 
C until assayed for eo-
taxin. Differential cell counts were performed on eosin and meth-
ylene blue–stained cytospin preparations. 500 cells were counted
per slide. After collection of BAL fluid, the lungs were excised,
the pulmonary artery cannulated, and the lungs flushed with 20
ml of saline containing 10 mM EDTA. Lung tissue was chopped
and weighed, and 
 
z
 
50% was processed immediately for EPO
measurement while the remainder was stored at 
 
2
 
80
 
8
 
C for sub-
sequent determination of lung eotaxin.
 
Modulation of the Inflammatory Response by TRFK5 and Dexa-
methasone.
 
TRFK5 mAb or control rat IgG (0.3 mg/kg) was in-
jected i.v. 45 min before saline or allergen challenge. Dexametha-
sone (40 mg/kg at each time point) or saline was given i.p. at 24
and 1 h before saline or ovalbumin challenge. Animals were
killed at 6 and 24 h after aerosol challenge.
 
Determination of Eosinophil Numbers in Bone Marrow.
 
The right
femur was isolated, the femoral head and condyles were removed,
and the displaceable cells were recovered by flushing the lumen
of the femur shaft with 5 ml HBSS (containing 30 mM Hepes,
0.25% BSA, and 10 U/ml heparin). The bone marrow suspension
was passed through a 19 gauge needle to create a single cell sus-
pension, and total nucleated cells were counted using Kimura
stain. Differential cell counts were performed on May-Grunwald-
Giemsa–stained cytospin preparations to determine the percent-
age of eosinophils. 400 cells were counted per slide.
 
Determination of Albumin in BAL Fluid.
 
Albumin was measured
using a fluorogenic substrate (26). BAL fluid was incubated with
8-anilino-1-naphthalenesulfonic acid sodium salt (2 
 
3
 
 10
 
2
 
4
 
 M, in
0.25 M sucrose/0.05 M Tris-HCl, pH 7.4) at room temperature
for 30 min and the fluorescence measured at 360 nm emission
and 460 nm excitation. Fluorescence was converted to albumin
concentration by reference to a guinea pig albumin standard
(0.015–0.5 mg/ml).
 
Lung Tissue Eosinophil Content Measured as EPO Activity.
 
Eosinophil numbers in lung tissue were quantitated as previously
described (27). Briefly, the tissue was homogenized to give a 5%
wt/vol suspension in HBSS and centrifuged (1,950 
 
g
 
, 10 min).
After red blood cell lysis, the pellet was homogenized to give a
5% suspension in HBSS containing 0.5% hexadecyltrimethylam-
monium bromide. The suspension was freeze/thawed three times
using liquid nitrogen before being stored at 
 
2
 
20
 
8
 
C until assayed.
After centrifugation, the lung extract was placed (75 
 
m
 
l/well, in
duplicate) in a 96-well plate followed by addition of 150 
 
m
 
l of
substrate (1.5 mM 
 
o
 
-phenylenediamine and 6.6 mM hydrogen
peroxide in 0.05 M Tris-HCl, pH 8.0). After 30 min at room
temperature, the reaction was stopped by the addition of 75 
 
m
 
l of
4 M sulfuric acid and the absorbance read at 492 nm. A standard
curve was prepared using guinea pig peritoneal eosinophils (see
below) after red blood cell lysis. The cross-reactivity with guinea
pig neutrophil myeloperoxidase was 
 
,
 
1%. Results are expressed
as eosinophils 
 
3
 
 10
 
6
 
/g lung tissue.
 
Production of Antieotaxin Antibodies.
 
Recombinant guinea pig
eotaxin was expressed in the bacterial host 
 
Escherichia coli
 
 as a fu-
sion protein under the control of the T7 polymerase system and
purified from inclusion bodies as previously described for
RANTES (28). Two rabbits were immunized with the recombi-
nant eotaxin (60 
 
m
 
g/rabbit) in Freund’s complete adjuvant and
boosted (100 
 
m
 
g/rabbit, in Freund’s incomplete adjuvant) 3 and
6 wk later. The animals were bled out 11 d after the final boost.
Diluted serum was used for the radioimmunoassays. For neu-
tralization studies, the IgG fraction was prepared by use of 
 
n
 
-octanoic
acid to precipitate unwanted proteins (29) followed by precipita-
tion of the IgG with 50% ammonium sulfate. For immunohis- 
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tochemistry, the IgG fraction was prepared by binding to protein
A–Sepharose CL-4B and elution with 0.1 M glycine-HCl, pH
3.0 (30). In both cases the IgG was made up to the original vol-
ume of serum, dialyzed against saline, filtered, and stored at
 
2
 
20
 
8
 
C in aliquots.
 
Lung Tissue Extraction for Eotaxin Measurement.
 
Frozen lung sam-
ples were homogenized to give a 10% wt/vol suspension in 0.2%
TFA and centrifuged at 4
 
8
 
C (3,470 
 
g
 
, 20 min). The supernatant
was neutralized by adding an equal volume of 0.01 M NaOH in
0.29 M NaCl/0.1 M sodium phosphate buffer, pH 7.4, and cen-
trifuged in a microfuge. The supernatant was then diluted with an
equal volume of PBS/0.05% sodium azide/22% polyethylene
glycol 6,000/1% protamine sulfate. After a second microcentrifu-
gation, the supernatant (equivalent to 2.5% lung homogenate)
was assayed for eotaxin.
 
RIA for Guinea Pig Eotaxin.
 
Guinea pig eotaxin (2.5 
 
m
 
g) was
iodinated (31) using iodogen reagent and Na
 
125
 
I (18.5 MBq). The
competitive binding assay protocol was similar to that described
previously for complement C5a (32). BAL fluid (100 
 
m
 
l, mixed
with 100 
 
m
 
l of PBS/azide/11% polyethylene glycol/0.5% prota-
mine sulfate) or lung tissue extract (100 
 
m
 
l, mixed with 100 
 
m
 
l of
the lavage medium) was incubated with 
 
125
 
I-ligand (50 
 
m
 
l, 30
fmol) and antiserum (50 
 
m
 
l of 1:700 dilution) (both in 0.2 M so-
dium phosphate buffer, pH 7.4, containing 0.3% BSA/10 mM
EDTA/azide). After 20–24 h at room temperature, 25 
 
m
 
l of goat
anti–rabbit IgG was added and the samples incubated for a further
8–16 h. Addition of 1 ml of PBS/azide was rapidly followed by
centrifugation (5,420 
 
g
 
, 10 min) and aspiration of the supernatant.
Ab-bound radioactivity in the pellet was counted in a gamma
counter and concentration calculated by comparison with a guinea
pig eotaxin standard curve. All samples were assayed in duplicate.
Nonspecific binding in the absence of antieotaxin was 3.06 
 
6
 
0.11% (mean
 
6
 
SEM, 
 
n
 
 
 
5
 
 48 assays). The limit of adequate mea-
surement (i.e., the concentration required to inhibit binding of
 
125
 
I-ligand by 20%) was 0.32 
 
6
 
 0.01 nM and 50% inhibition of
binding was achieved with 1.27 
 
6
 
 0.03 nM eotaxin (
 
n
 
 
 
5
 
 53). Us-
ing frozen aliquots of a sample of pooled BAL fluid, the interassay
coefficient of variation was 4.5% (
 
n
 
 
 
5
 
 23 assays) and the intraassay
coefficient of variation was 3.4% (six measurements in one assay).
Cross-reactivity of guinea pig MCP-1, RANTES and IL-8, hu-
man eotaxin, MCP 1, 2, 3, 4, MIP-1
 
a
 
, 
 
b
 
, RANTES, and murine
eotaxin (all assayed at 100 nM) was 
 
,
 
1%.
 
Bioassay of Eosinophil Chemoattractant Activity in Naive Guinea
Pig Skin.
 
Eosinophils, harvested from the peritoneal cavity of
female exbreeder guinea pigs (800–900 g) given repeated i.p. in-
jections of horse serum, were purified (
 
.
 
95%) over discontinu-
ous Percoll gradients and radiolabeled with 
 
111
 
In as previously de-
scribed (33). 
 
111
 
In-eosinophils (5 
 
3
 
 10
 
6
 
) were injected i.v. via an
ear vein and, 5 min later, test agents were injected intradermally
(i.d.) (0.1 ml) into the shaved dorsal skin of naive recipient guinea
pigs (400 g). To determine the neutralizing capacity of antieo-
taxin IgG, eotaxin (1.5 pmol/site), purified from guinea pig BAL
fluid (16), was coinjected i.d. with various amounts of antieotaxin
(0, 1, 3, 10, and 30 
 
m
 
l) or control IgG (30 
 
m
 
l). To investigate
eosinophil chemoattractant activity in BAL fluid, obtained 6 h af-
ter aerosolized saline or ovalbumin, samples were concentrated by
use of C18 reversed phase SepPak cartridges, eluted with acetoni-
trile in 0.1% trifluoroacetic acid, lyophilized, and redissolved in
HBSS/0.1% BSA (
 
,
 
0.1 ng endotoxin/mg albumin). Samples
were then coinjected i.d. with 50 
 
m
 
l antieotaxin or control IgG
such that the final concentration factor of the BAL fluid was 18-
fold. After 4 h, the animals were killed, the dorsal skin removed,
and the injection sites punched out (17 mm diameter) for gamma
 
counting. Radiolabeled cell accumulation is expressed as the num-
ber of 
 
111
 
In-eosinophils per skin site.
 
Immunohistochemistry.
 
 Immediately after killing and without
performing BAL, the lungs were inflated via the trachea with 4%
paraformaldehyde in PBS, and fixed by immersion for 4 h at 4
 
8
 
C,
transferred into 15% sucrose in PBS, and processed as paraffin
blocks. 6-
 
m
 
m sections were cut and mounted on poly 
 
l
 
-lysine–
coated slides. Hematoxylin and eosin–stained sections were used
to assess the morphological changes associated with sensitization
and allergen challenge. For the immunohistological localization
of eotaxin the slides were treated in 0.2% H
 
2
 
O
 
2
 
 in absolute etha-
nol to block endogenous staining and the primary polyclonal an-
tibody (1:100 dilution) was added and incubated for 1 h at room
temperature. After washing in Tris-buffered saline, a second layer
mouse anti–rabbit IgG mAb (1:50 dilution) was added, followed
by a third layer rabbit anti–mouse antibody conjugated with horse-
radish peroxidase (1:50 dilution). The substrate solution (3-amino-
9-ethyl carbazole) was used to produce a dark red precipitate
wherever the primary antibody detected eotaxin. Normal guinea
pig IgG (1:100 dilution) was substituted for the primary antibody
as negative control.
 
Statistical Analysis.
 
Results are presented as the mean
 
6
 
SEM
of n animals. Analysis of skin bioassay responses was carried out
on log10-transformed data using repeated measures ANOVA. All
other data were analyzed on untransformed data using an un-
paired two-tailed Student’s t test. P ,0.05 was considered to be
statistically significant.
Results
Relationship between the Kinetics of Albumin and Eosinophil
Accumulation in BAL. Sensitized guinea pigs were chal-
lenged with aerosolized ovalbumin and BAL samples were
collected at intervals up to 24 h later. Groups of 5–11 ani-
mals were used to generate data at each time point. As
shown in Fig. 1 plasma albumin concentrations rose rapidly
during an early phase from 0–6 h and remained high up to
24 h. In contrast, there was a protracted delay before signif-
Figure 1. Time course of albumin extravasation (d, solid line) and
eosinophil accumulation (j, dotted line) in BAL after allergen challenge.
Sensitized guinea pigs were exposed to aerosolized ovalbumin and killed
at various times after challenge. Results are presented as a mean6SEM of
5–11 animals/time point. 0 h represents sensitized/nonchallenged animals
(n 5 5). Significant differences from 0 h are indicated as *P ,0.02 and **P
,0.005. Basal eosinophil numbers in BAL are shown by the dashed line.604 Eotaxin Generation and Eosinophil Accumulation in Allergic Airways
icant eosinophil numbers appeared in the BAL: only low
numbers were present at 12 h, but accumulation was rapid
between 12 and 24 h. Thus, microvascular leakage corre-
lated mainly with an early phase of the allergic response
whereas eosinophils appeared in BAL mainly in a late phase
after an apparent protracted latent period.
Correlation between the Kinetics of Eosinophil Infiltration and
the Appearance of Immunoreactive Eotaxin. Fig. 2 A shows
that there was a dissociation between eosinophil accumula-
tion and the presence of immunoreactive eotaxin when
measured in BAL samples. Eotaxin rose to high levels at 6 h
at a time when eosinophil numbers were not significantly
elevated, but fell to low levels by 12 h, at a time when eo-
sinophil accumulation was beginning to accelerate.
In contrast, there was a good correlation between the
appearance of eotaxin and eosinophil accumulation when
measured by EPO assay in lung tissue extracts. However,
levels of the chemokine again fell by 12 h, whereas the
eosinophil numbers remained high up to 24 h (Fig. 2 B).
Most previous studies have determined kinetics of eosino-
phil accumulation from BAL samples which exhibit a clear
delayed response in terms of eosinophil accumulation, as
seen in Fig. 2 A. Results from this model suggest that eosin-
ophil accumulation in lung tissue occurs much earlier. Thus,
eosinophil recruitment through the endothelium of airway
blood microvessels appears to be rapid, whereas extensive
traffic through the airway epithelium is considerably de-
layed.
Neutralization of Eosinophil Chemoattractant Activity in BAL
Fluid. Fig. 3 A shows that a polyclonal antibody gener-
ated to recombinant guinea pig eotaxin completely blocked
111In-eosinophil accumulation when mixed with eotaxin
and injected into guinea pig skin. The neutralizing anti-
body was then used to investigate the contribution of eo-
taxin to eosinophil chemoattractant activity in BAL fluid
tested in the skin. Addition of the antieotaxin antibody vir-
tually abolished the chemoattractant activity in BAL fluid
from allergen challenged animals as well as the lesser amount
of bioactivity in fluid from the control groups of naive and
sensitized animals exposed to saline (Fig. 3 B). The eosino-
Figure 2. Time course of eotaxin generation (d, solid line) and eosino-
phil accumulation (j, dotted line) in (A) BAL and (B) lung tissue of sensi-
tized guinea pigs after allergen challenge. Results are presented as a
mean6SEM (n 5 5–9 animals/time point). 0 h represents sensitized/
nonchallenged animals (n 5 5). Significant differences from 0 h are indi-
cated as *P ,0.05 and **P ,0.005. Constitutive levels of eotaxin in BAL
fluid and lung tissue are shown by the dashed lines.
Figure 3. (A) Inhibition of eotaxin-induced 111In-eosinophil accumu-
lation by antieotaxin antibody. Purified eotaxin (1.5 pmol) was coinjected
with antieotaxin IgG (j, 1–30 ml), control IgG (r, 30 ml) or without
IgG (d, upper dotted line) into the skin of naive guinea pigs that had re-
ceived an i.v. injection of 111In-eosinophils. Results are presented as a
mean6SEM of 111In-eosinophils/skin site after 4 h (n 5 4–6 bioassay an-
imals). Responses to the intradermal vehicle (HBSS/0.25% BSA) alone
are shown by the lower dotted line. Antieotaxin (h, 30 ml) or control
IgG (e, 30 ml) added to the HBSS/BSA did not induce significant 111In-
eosinophil accumulation. (B) Inhibition of 111In-eosinophil chemoattrac-
tant activity in 6 h BAL fluid by antieotaxin antibody. BAL fluid obtained
6 h after exposure of naive or sensitized guinea pigs to aerosolized saline
or ovalbumin was concentrated by C18 SepPak chromatography (see Ma-
terials and Methods) and coinjected with 50 ml control IgG (open bars) or
antieotaxin IgG (solid bars) into the skin of naive guinea pigs which had
received an i.v. injection of 111In-eosinophils. Responses to HBSS/BSA 1
control IgG or antieotaxin antibodies were also determined. Results are
presented as a mean6SEM (n 5 4 bioassay animals) and significant differ-
ences between control IgG and antieotaxin IgG treated samples are indi-
cated as *P ,0.01. Eotaxin concentrations in unconcentrated BAL fluid
(cross hatched bars) are also shown in B. Eotaxin in lung tissue was 28.6 6
2.5, 24.9 6 2.1, and 89.6 6 3.0 pmol/g (mean6SEM, n 5 5) in the na-
ive/saline, sensitized/saline, and sensitized/ovalbumin groups, respec-
tively. When these results are expressed as total eotaxin per guinea pig
lung, there was approximately five to six times more eotaxin in lung tissue
(114 6 8, 115 6 16, and 379 6 14 pmol) than in BAL fluid (23 6 3, 18 6
4, and 82 6 10 pmol, respectively).605 Humbles et al.
phil chemoattractant activity in BAL fluid correlated closely
with the level of immunoreactive eotaxin (Fig. 3 B). As
shown for eotaxin mRNA in the lung (23, 24), there was
significant eotaxin protein in the fluid from naive/saline-
and sensitized/saline-exposed animals which was markedly
elevated in the sensitized/ovalbumin-challenged animals
(Fig. 3 B). Data for eotaxin levels in the lung tissue from
these animals are given in the legend to Fig. 3 and demon-
strate that, in terms of total eotaxin per guinea pig, there
was five to six times more in the lung tissue than in BAL
fluid in all three groups.
Effects of Dexamethasone on Allergen-induced Eosinophil Ac-
cumulation and Immunoreactive Eotaxin Levels in BAL Fluid
and Lung Tissue. Fig. 4 shows the effects of dexametha-
sone pretreatment on eosinophil accumulation in the lungs
of sensitized/ovalbumin-challenged animals. The glucocor-
ticoid markedly suppressed eosinophil accumulation in lung
tissue and virtually eliminated their appearance in the BAL.
However, as shown in Fig. 5, this effect was not the result
of suppression of eotaxin generation, dexamethasone hav-
ing no significant effect on levels of immunoreactive eo-
taxin.
Effect of a Neutralizing Antibody to IL-5 on Allergen-induced
Eosinophil Accumulation and Immunoreactive Eotaxin Levels in
BAL Fluid and Lung Tissue. In a previous study (16) we
found no evidence of eosinophil chemoattractant activity
corresponding to IL-5 in BAL fluid from sensitized/oval-
bumin-challenged guinea pigs. However, pretreatment of
animals with a neutralizing antibody to IL-5, TRFK5,
markedly suppressed allergen-induced eosinophil accumu-
lation in lung tissue and BAL in sensitized animals (Fig. 6,
A and B). The antibody also significantly reduced eosino-
phil numbers in the lung tissue of sensitized animals 6 h af-
ter aerosolized saline. TRFK5 had no significant effect on
the numbers of mononuclear cells or neutrophils in BAL
(data not shown) or on the levels of eotaxin in BAL fluid
and lung tissue (Fig. 6, C and D).
Effect of a Neutralizing Antibody to IL-5 on Numbers of Eosin-
ophils in the Bone Marrow After Allergen Challenge. In the same
experiment as described above using TRFK5, the bone mar-
row in the femur was used to detect possible changes in the
eosinophil population after allergen challenge. Fig. 7 (open
bars) shows the marked reduction in bone marrow eosino-
phils in sensitized guinea pigs at 6 and 24 h after allergen
challenge, compared to saline challenge at 6 h. This reduc-
tion was blocked by the antibody to IL-5. In fact, in all
cases the antibody treatment increased bone marrow eosin-
ophils when compared with numbers in the samples taken
6 h after saline (Fig. 7, closed bars) indicating that basal re-
lease of eosinophils was blocked as well as allergen-induced
release.
Evidence for a Rapid Movement of Eosinophils from the Bone
Marrow to the Lung in Response to Allergen Challenge. Sen-
Figure 4. Effect of dexamethasone on allergen-induced eosinophil ac-
cumulation in (A) BAL and (B) lung tissue. Sensitized guinea pigs were
injected i.p. with dexamethasone (40 mg/kg) or saline at 24 and 1 h be-
fore allergen challenge. 0 h represents sensitized/nonchallenged animals
(n 5 5). Results are presented as mean6SEM (n 5 5–11 allergen-chal-
lenged animals/time point) and significant differences between dexa-
methasone- and saline-treated groups are indicated as *P ,0.05 and **P
,0.005. Basal eosinophil numbers in BAL and lung tissue are shown by
the dashed lines.
Figure 5. Effect of dexamethasone on allergen-induced eotaxin gener-
ation in (A) BAL fluid and (B) lung tissue. Sensitized guinea pigs were in-
jected i.p. with dexamethasone (40 mg/kg) or saline at 24 and 1 h before
allergen challenge. 0 h represents sensitized/nonchallenged animals (n 5 5).
Results are presented as mean6SEM (n 5 5–11 allergen-challenged ani-
mals/time point). Constitutive levels of eotaxin in BAL and lung tissue
are shown by the dashed lines.606 Eotaxin Generation and Eosinophil Accumulation in Allergic Airways
sitized guinea pigs were challenged with aerosolized oval-
bumin and the numbers of eosinophils monitored at inter-
vals up to 6 h in the bone marrow of the femur, peripheral
blood, and lung tissue. Allergen challenge resulted in a
rapid and progressive reduction in bone marrow eosino-
phils which was mirrored by a marked rise in peripheral
blood eosinophils (Fig. 8, A and B). The results presented
in Fig. 7 indicate that this mobilization of eosinophils was
mediated by endogenous IL-5. As shown in Fig. 8 C, eosin-
ophils were rapidly recruited into the lung tissue where the
eosinophil numbers correlated with increased eotaxin levels
at 3 and 6 h. The speed of eosinophil recruitment into lung
tissue contrasts with their slow migration into the airway
lumen as evidenced by their late appearance in BAL sam-
ples (as shown in Fig. 1).
Morphological Changes and Cellular Localization of Eotax-
in. In comparison with the sensitized/nonchallenged ani-
mals, sensitized/ovalbumin-challenged guinea pig lungs
showed pronounced eosinophil infiltration of airway epi-
thelium and surrounding interstitial tissues (Fig. 9 B). The
eosinophilic infiltrate was associated with both airways and
pulmonary arteries. In the edematous interstitial tissues be-
tween large airways and pulmonary artery, there were also
neutrophils and mononuclear cells. Goblet cell hyperplasia
was evident in large intrapulmonary airways. In small (dis-
tal) airways, changes included marked epithelial hyperplasia
and epithelial folding associated with airways contraction and
obstruction of the airway lumina. The parenchyma of the
lung was congested and macrophages in alveoli surround-
ing the airways were increased in number.
Immunohistochemical staining with anti–guinea pig eo-
taxin was strongest and most abundant in the lungs of sensi-
tized/ovalbumin-challenged animals (Fig. 9 D). In the large
airways, eotaxin positivity was present in the airway epithe-
lium and appeared to be confined to ciliated cells and the
basal aspects of other epithelial cells. Bronchial smooth mus-
cle immunostained strongly while vascular smooth muscle
of large pulmonary vessels was negative. However, bron-
chial vessels in the lamina propria and the submucosa were
positive. In bronchioli, the positive staining was localized
to nonciliated epithelial (Clara) cells. Alveolar macrophages
showed strong positivity only in the allergen-challenged
animals (Fig. 9 E). There were also eotaxin-positive in-
flammatory cells in the tissue but the cell type could not be
identified in this study. Sensitized/nonchallenged and naive
animals showed constitutive staining particularly of bron-
chial smooth muscle and cartilage chondrocytes, and weak
staining of apices of epithelial cells and, only occasionally,
of alveolar macrophages. The negative control sections, in
which the antieotaxin IgG was replaced by control IgG,
showed very weak diffuse staining not localized to any tis-
sue structure. A detailed light and electron microscopic
study of guinea pig eotaxin immunolocalization is to be
published separately.
Discussion
We have analyzed the kinetics of eosinophil accumula-
tion in the lung using a model of allergic airways inflamma-
tion and have examined the association with levels of im-
Figure 6. Effect of an anti–IL-5 antibody, TRFK5, on eosinophil numbers in (A) BAL and (B) lung tissue, and eotaxin levels in (C) BAL fluid and (D)
lung tissue after allergen challenge. Sensitized guinea pigs were injected i.v. with control rat IgG or TRFK5 (0.3 mg/kg) 30 min before aerosol exposure
to saline or allergen. Results are presented as mean6SEM (n 5 5–6 animals/group) and significant differences between control IgG and TRFK5-treated
groups are indicated as *P ,0.05 and **P ,0.005.607 Humbles et al.
munoreactive eotaxin. Previous extensive investigations in
animals and humans have demonstrated that allergen chal-
lenge induces an immediate mast cell–mediated acute bron-
chospasm and a late bronchospasm associated with appear-
ance of eosinophils. In these studies sampling by BAL
revealed an apparent protracted latent period before the de-
layed accumulation of eosinophils (8, 11, 13–15, 34, 35).
These results are consistent with those in Fig. 1, which shows
two apparently distinct phases of the allergic response: an
early phase of increased microvascular permeability as evi-
denced by increasing concentrations of albumin in BAL
fluid, and a delayed phase of eosinophil accumulation in
BAL from 12–24 h. This eosinophil influx into the airway
lumen is apparently at variance with the kinetics of eotaxin
levels: BAL and tissue eotaxin levels peaked at 6 h and fell
to low levels by 12 h (Fig. 2).
Measurement of changes in lung tissue (Figs. 2 B and 8
C) throws light upon this apparent disassociation. We sug-
gest the following sequence of events. Allergen challenge
stimulates mast cell activation; degranulation products in-
duce acute bronchoconstriction, and contribute to mucus
secretion and increased microvascular permeability. Plasma
proteins can readily pass through the airway epithelium and
were detected in this study as increasing albumin concen-
trations over 0–6 h in BAL fluid (Fig. 1). Mast cell products
may also mediate very early eosinophil accumulation: ad-
herent eosinophils were seen histologically in microvessels
within a few minutes of challenge in a previous study (12)
and a significant increase in tissue eosinophils was detected at
1 h in our investigation (Fig. 8 C). Lung tissue eotaxin was
significantly elevated at 3 h after allergen challenge, rising
to a peak at 6 h and falling to low levels by 12 h (Fig. 2 B).
Immunostaining suggested upregulation, particularly in air-
way epithelial cells and inflammatory cells such as mac-
rophages (Fig. 9). Eosinophil levels in the tissue closely fol-
lowed eotaxin levels up to 6 h, but the cells persisted until
the last measurement time point at 24 h (Figs. 2 B and 8 C)
probably influenced by factors increasing cell survival such as
IL-5 (see below). Eotaxin generated in the tissue would be
expected to pass from and through the airway epithelium
into the lumen and indeed a similar eotaxin time course as
in the tissue was seen in BAL fluid (Fig. 2 B). Close inspec-
tion of the eotaxin levels in BAL fluid and lung tissue (Fig.
2) suggests that eotaxin is cleared or metabolized faster
from the lung tissue than from the lumen. Thus, while eo-
taxin is being generated in the lung tissue, a gradient be-
tween the tissue and the microvessel lumen will facilitate
traffic across the vascular endothelium. However, during
active chemokine secretion the eotaxin concentration in
Figure 7. Effect of an anti–IL-5 antibody, TRFK5, on eosinophil
numbers in bone marrow after allergen challenge. Sensitized guinea pigs
were injected i.v. with control rat IgG or TRFK5 (0.3 mg/kg) 30 min
before aerosol exposure to saline or allergen. Results are presented as
mean6SEM (n 5 5–6 animals/group) and significant differences between
control and TRFK5-treated groups are indicated as *P ,0.02 and **P
,0.005.
Figure 8. Eosinophil numbers (solid bars) in (A) femur bone marrow,
(B) blood, and (C) lung tissue after allergen challenge. Sensitized guinea
pigs were exposed to aerosolized ovalbumin and killed at various times af-
ter challenge. 0 h represents sensitized/nonchallenged animals. Eotaxin
levels in lung tissue are shown as the open bars. Results are presented as
mean6SEM (n 5 4–5 animals/time point) and significant differences
from 0 h are indicated as *P ,0.03 and **P ,0.001.608 Eotaxin Generation and Eosinophil Accumulation in Allergic Airways609 Humbles et al.
the fluid lining the airway will be lower than in the tissue
and the direction of the gradient will inhibit migration into
the airway lumen. Subsequently, when eotaxin secretion
ceases, clearance and metabolism in the tissue may reverse
the gradient across the epithelium, thus facilitating migra-
tion into the airway lumen over the 12–24 h period.
The immunoreactive eotaxin in the BAL fluid from
ovalbumin-challenged and saline-challenged animals was ac-
tive as a chemoattractant. Concentrated BAL fluid injected
intradermally into bioassay animals induced 111In-eosino-
phil accumulation. This activity was virtually abolished when
the sample was mixed with a neutralizing antibody to eo-
taxin (Fig. 3 B). It has been shown previously that the
guinea pig lung has a constitutive eotaxin mRNA signal,
suggesting that eotaxin may be responsible for maintaining
the basal level of eosinophils found in the lung in this spe-
cies (23, 24). This is supported by eotaxin protein levels
measured by immunoassay and skin bioassay in samples
from naive and sensitized/saline-exposed animals (Fig. 3 B).
Immunostaining showed constitutive eotaxin particularly in
cartilage chondrocytes and bronchial smooth muscle cells,
the latter now recognized as a source of chemokines (36).
Although the neutralizing antibody blocked the eosinophil
chemoattractant activity in BAL fluid from sensitized/aller-
gen-challenged animals, we were unable to suppress eosino-
phil accumulation in the lung when the antibody was ad-
ministered intravenously (Humbles, A.A., unpublished data).
The reason for this is unclear, but the results could reflect a
contribution from other (possibly unstable) chemoattrac-
tants. Alternatively, eotaxin bound to extracelluar matrix in
the lung may act as a sink for antibody. Higher affinity an-
tibodies may be required for effective systemic treatment.
We were interested in possible effects of an antiinflam-
matory compound on eotaxin generation in the allergen
challenge model. Dexamethasone suppressed eosinophil ac-
cumulation in the lung tissue and airways but had no sig-
nificant effect on eotaxin levels (Figs. 4 and 5). This sug-
gests that the glucocorticoid inhibited eosinophil migration
through the microvascular endothelium by some mecha-
nism independent of eotaxin release in this model. This
may at least be partly due to inhibition of the release or ac-
tion of IL-5, which is important in this model (see below).
Inhibition of eosinophil accumulation into the airway lu-
men was even greater than into tissue, indicating a further
action of dexamethasone on eosinophil migration through
the airway epithelium. The reported inhibitory effects of
glucocorticoids on eosinophil survival (37, 38) may con-
tribute to the latter effect. An incidental observation from
these experiments is that eosinophils themselves are un-
likely to be a major source of lung eotaxin over the time
period studied because marked suppression of eosinophil
accumulation had no detectable effect on eotaxin levels.
IL-5 has an important role in eosinophil accumulation in
allergen-challenged lungs. As shown in Fig. 6, an IL-5 neu-
tralizing antibody, TRFK5, effectively suppressed eosinophil
accumulation in the lung tissue and BAL after allergen chal-
lenge. Other laboratories have taken such results as evidence
that IL-5 is an important eosinophil chemoattractant. How-
ever, we found no evidence of IL-5 eosinophil chemoat-
tractant activity in HPLC fractions of BAL fluid from sensi-
tized/challenged guinea pigs in previous studies (16, 39).
Further, endogenous IL-5 does not appear to regulate eo-
taxin generation as TRFK5 had no effect on eotaxin levels
in the lung (Fig. 6). We have shown recently that intrave-
nous IL-5 rapidly releases eosinophils from the bone mar-
row into the blood of naive guinea pigs and that this po-
tentiates eosinophil recruitment into skin sites injected with
eotaxin (25). The results presented here suggest that this phe-
nomenon extrapolates to the allergic inflammation model,
as allergen challenge of the lung resulted in a decrease in
bone marrow eosinophils (Figs. 7 and 8). The eosinophils
progressively moved out of the bone marrow, beginning
within 1 h of aerosolized allergen challenge, and were seen
in higher numbers in the blood and lung within 3 h. This
release of eosinophils appears to be mediated by IL-5 since
it was inhibited by TRFK5. In fact, TRFK5 increased the
retention of bone marrow eosinophils with or without al-
lergen challenge (Fig. 7) suggesting that constitutive IL-5
regulates basal release of eosinophils. IL-5 will also have ef-
fects other than causing acute release of a preformed pool
of eosinophils, e.g., in the short term priming eosinophils
for recruitment, in the longer term prolonging eosinophil
survival in the tissue and inducing proliferation and differ-
entiation of bone marrow eosinophils. Our results using
TRFK5 are consistent with those of Foster et al. (40) who
have shown that the eosinophilia, lung damage, and air-
ways hyperresponsiveness resulting from allergen challenge
were abolished in IL-5–deficient mice.
The results presented here suggest that allergen provoca-
tion of the lung in the sensitized guinea pig stimulates a
rapid movement of eosinophils from the bone marrow via
the blood to the lung (Fig. 8) which involves the coopera-
tive effort of IL-5 and eotaxin. We propose that allergen
stimulates the production of IL-5 and eotaxin in the lung.
IL-5 is carried by the blood to the bone marrow where it
mobilizes eosinophils into the circulation. Eotaxin then has
Figure 9. (A and B) Hematoxylin and eosin and (C–E) immunostaining for eotaxin in sections of hilar intrapulmonary airways from (A and C) sensi-
tized/nonchallenged and (B and D) sensitized guinea pigs 3 h after allergen challenge. In the nonchallenged animals the epithelial and subepithelial tissues
have few eosinophils while there is heavy infiltration of the mucosa by eosinophils after challenge. Immunolabeling with polyclonal antieotaxin IgG
shows relatively weak staining in the absence of challenge compared with strong immunopositivity of epithelial cells, inflammatory cell infiltrate, and
bronchial smooth muscle after challenge. The strong immunostaining of macrophages in the alveoli, after challenge, is demonstrated in E. (F) Immuno-
histology of an airway plug from a patient who had a fatal asthma attack. The sample was fixed in formalin, embedded in paraffin, immunostained with
EG2, and counter-stained with nuclear fast red. There are concentric rings of activated eosinophils as shown by their immunopositivity for EG2 (41, 42).
Magnification: A–D 3640, E 3320, F 3600.610 Eotaxin Generation and Eosinophil Accumulation in Allergic Airways
the role of recruiting eosinophils from the microvascula-
ture. These effects begin surprisingly rapidly after allergen
challenge and the onset of eosinophil recruitment occurs
during the early phase of microvascular protein leakage and
increased mucus secretion. When sampling from the airway
lumen there is an apparent wide separation between early
and late inflammatory components of the allergic response,
as shown in Fig. 1. We suggest that this is largely artifactual:
protein leaking from blood microvessels moves rapidly
through the airway epithelium, whereas the movement of
eosinophils into the airway lumen is delayed, giving the
late cellular response. The numbers of activated eosinophils
in the airway wall would be expected to be most relevant
to changes in the lung function. Indeed, experimentally
and clinically the onset of the late bronchoconstrictor re-
sponse occurs at 4–12 h, corresponding to the phase of high
tissue eosinophilia in our study.
If similar events occur in the lungs of asthmatic patients
it is not difficult to imagine repeated allergen provocation
giving rise to waves of infiltration of eosinophils and in-
creasing damage to lung tissue. Asynchronous phases of
protein and eosinophil movement into the airway lumen
would be predicted by analogy with the results in Fig. 1.
This could give rise to the concentric rings of protein and
eosinophils seen in airway plugs of fatal asthma as graphi-
cally illustrated in Fig. 9 F.
We suggest that eotaxin and related chemokines acting
through the eotaxin CCR3 receptor may play a major role
in eosinophil recruitment into the asthmatic lung and thus
offer an attractive target for therapeutic intervention.
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